Trial reportGenes2026
Evaluation of Candidate Urinary microRNAs in Upper Tract Urothelial Carcinoma: A Prospective Multicenter Biomarker Study (JCOG1403A1).
Trial report in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesTo evaluate the clinical associations of candidate urinary microRNAs (miRNAs) in patients with upper tract urothelial carcinoma (UTUC), including their ability to discriminate patients with UTUC from healthy controls and their associations with relapse-free survival (RFS).
methodsThis prospective multicenter ancillary study of the JCOG1403 trial (JCOG1403A1 study) included 45 patients with UTUC and 16 healthy controls. Four candidate miRNAs (miR-130b, miR-182, miR-191, and miR-200a) were selected based on prior exploratory sequencing analysis. Urinary cell fractions were isolated by cell sorting, and miRNA expression was quantified by stem-loop RT-qPCR. The ability of urinary miRNAs to discriminate patients with UTUC from healthy controls, their associations with clinicopathological characteristics, and their associations with RFS were evaluated.
resultsAmong the candidate miRNAs, miR-191 and miR-200a showed significantly increased expression in patients with UTUC and demonstrated favorable discrimination between patients with UTUC and healthy controls. The combined miR-191/miR-200a model showed the highest discriminatory performance (area under the curve, 0.888). Urine cytology was positive in 33.3% of evaluable patients, whereas urinary miR-191 and miR-200a were detectable in 78.6% and 85.7% of patients with negative/suspicious cytology, respectively. Preoperative urinary miR-182 and miR-191 detectability was significantly associated with pathological tumor stage. In exploratory prognostic analyses, patients with detectable postoperative urinary miR-130b had significantly shorter RFS (log-rank
conclusionsUrinary miR-191 and miR-200a showed potential for discriminating patients with UTUC from healthy controls and may complement urine cytology, particularly in patients with negative/suspicious cytology. The association between postoperative urinary miR-130b detectability and RFS should be considered exploratory and requires further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.